New Results for GSK's Pre-Pandemic Flu Vaccine

March 22, 2007
BioPharm International Editors

GlaxoSmithKline (London, UK, www.gsk.com) has announced clinical trial data from two new studies, which show that its pre-pandemic flu vaccine, formulated with GSK's proprietary adjuvant system, works against diverse strains of H5N1.

GlaxoSmithKline (London, UK, www.gsk.com) has announced clinical trial data from two new studies, which show that its pre-pandemic flu vaccine, formulated with GSK’s proprietary adjuvant system, works against diverse strains of H5N1. It is hoped that the immune response elicited with this vaccine could help prepare the immune system to rapidly respond against other versions of the virus. This could enable the company to produce large quantities of the product for mass vaccination in the event of an H5N1 human pandemic.

Related Content:

News